UBXN7

Summary

UBXN7 (UBX domain protein 7, HGNC:29119) is a protein-coding gene on chromosome 3q29, encoding UBX domain-containing protein 7 (O94888). Ubiquitin-binding adapter that links a subset of NEDD8-associated cullin ring ligases (CRLs) to the segregase VCP/p97, to regulate turnover of their ubiquitination substrates.

Enables RNA polymerase II-specific DNA-binding transcription factor binding activity; ubiquitin binding activity; and ubiquitin protein ligase binding activity. Predicted to be involved in proteasome-mediated ubiquitin-dependent protein catabolic process. Located in nucleoplasm. Part of VCP-NPL4-UFD1 AAA ATPase complex.

Source: NCBI Gene 26043 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 42 total
• MANE Select transcript: NM_015562

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29119
Approved symbol	UBXN7
Name	UBX domain protein 7
Location	3q29
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0794
Ensembl gene	ENSG00000163960
Ensembl biotype	protein_coding
OMIM	616379
Entrez	26043

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000296328, ENST00000381887, ENST00000413584, ENST00000428095, ENST00000429160, ENST00000493566, ENST00000897727, ENST00000897728, ENST00000938274

RefSeq mRNA: 1 — MANE Select: NM_015562 NM_015562

CCDS: CCDS43191

Canonical transcript exons

ENST00000296328 — 11 exons

Exon	Start	End
ENSE00001265446	196347662	196356846
ENSE00001747224	196391813	196391925
ENSE00003528738	196402952	196403019
ENSE00003553873	196407246	196407393
ENSE00003595619	196432327	196432427
ENSE00003600928	196393554	196393619
ENSE00004035133	196371896	196372042
ENSE00004035135	196362294	196362687
ENSE00004035136	196368028	196368155
ENSE00004035137	196369421	196369511
ENSE00004035138	196361844	196361923

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 91.78.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 27.9351 / max 348.1546, expressed in 1811 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
46352	27.4849	1810
203077	0.4502	233

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endometrium epithelium	UBERON:0004811	91.78	gold quality
colonic epithelium	UBERON:0000397	91.68	gold quality
nipple	UBERON:0002030	91.61	gold quality
sperm	CL:0000019	91.31	gold quality
cranial nerve II	UBERON:0000941	90.99	gold quality
cartilage tissue	UBERON:0002418	90.20	gold quality
cervix squamous epithelium	UBERON:0006922	89.86	gold quality
cortical plate	UBERON:0005343	89.71	gold quality
hair follicle	UBERON:0002073	89.70	gold quality
corpus epididymis	UBERON:0004359	89.64	gold quality
sural nerve	UBERON:0015488	89.63	gold quality
mammary duct	UBERON:0001765	89.51	gold quality
calcaneal tendon	UBERON:0003701	89.47	gold quality
ganglionic eminence	UBERON:0004023	89.44	gold quality
ventricular zone	UBERON:0003053	89.19	gold quality
caput epididymis	UBERON:0004358	89.06	gold quality
endothelial cell	CL:0000115	88.96	gold quality
male germ cell	CL:0000015	88.80	gold quality
corpus callosum	UBERON:0002336	88.52	gold quality
epithelium of mammary gland	UBERON:0003244	88.43	gold quality
paraflocculus	UBERON:0005351	88.34	gold quality
cauda epididymis	UBERON:0004360	88.05	gold quality
buccal mucosa cell	CL:0002336	87.67	gold quality
adrenal tissue	UBERON:0018303	87.17	gold quality
bone marrow cell	CL:0002092	86.97	gold quality
mucosa of paranasal sinus	UBERON:0005030	86.78	gold quality
tonsil	UBERON:0002372	86.68	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.54	gold quality
saphenous vein	UBERON:0007318	86.29	gold quality
inferior vagus X ganglion	UBERON:0005363	85.99	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	5.58
E-HCAD-5	no	2.20

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

162 targeting UBXN7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-98-3P	100.00	74.08	3907
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-3688-3P	99.97	72.02	2834

Literature-anchored findings (GeneRIF, showing 9)

• UBXD7 links p97 to the ubiquitin ligase CUL2/VHL and its substrate hypoxia-inducible factor 1alpha (HIF1alpha). (PMID:18775313)
• FAF1 and UBXD7 only bind to p97-UFD1/NPL4, but not free p97, thus demonstrating for the first time a hierarchy in p97-cofactor interactions (PMID:21645854)
• Study finds that UBXN7 over-expression converts CUL2 to its neddylated form and causes the accumulation of non-ubiquitylated HIF1alpha. (PMID:22537386)
• Data suggest that dimerization of UBX domain protein 7 (UBXD7) could affect the formation of the p97 ATPase-UBXD7 complex. (PMID:28274878)
• [Circular RNA-UBXN7 promotes proliferation, migration and suppresses apoptosis in hepatocellular cancer]. (PMID:32536059)
• UBXN7 cofactor of CRL3(KEAP1) and CRL2(VHL) ubiquitin ligase complexes mediates reciprocal regulation of NRF2 and HIF-1alpha proteins. (PMID:33444648)
• HBV X Protein Induces Degradation of UBXN7, a Novel Negative Regulator of NF-kappaB Signaling, to Promote HBV Replication. (PMID:36096451)
• CircUBXN7 suppresses cell proliferation and facilitates cell apoptosis in lipopolysaccharide-induced cell injury by sponging miR-622 and regulating the IL6ST/JAK1/STAT3 axis. (PMID:36257578)
• CircUBXN7 promotes macrophage infiltration and renal fibrosis associated with the IGF2BP2-dependent SP1 mRNA stability in diabetic kidney disease. (PMID:37744330)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ubxn7	ENSDARG00000009436
mus_musculus	Ubxn7	ENSMUSG00000053774
rattus_norvegicus	AABR07034438.1	ENSRNOG00000046969

Paralogs (4): UBXN8 (ENSG00000104691), FAF2 (ENSG00000113194), UBXN10 (ENSG00000162543), FAF1 (ENSG00000185104)

Protein

Protein identifiers

UBX domain-containing protein 7 — O94888 (reviewed: O94888)

All UniProt accessions (5): C9JAT7, C9JD50, O94888, F8WB69, H7BYF4

UniProt curated annotations — full annotation on UniProt →

Function. Ubiquitin-binding adapter that links a subset of NEDD8-associated cullin ring ligases (CRLs) to the segregase VCP/p97, to regulate turnover of their ubiquitination substrates.

Subunit / interactions. Interacts with neddylated CUL2, ubiquitinated HIF1A, and VCP/p97.

Subcellular location. Nucleus.

Domain organisation. The UIM (ubiquitin-interacting motif) is required to engage the NEDD8 modification on cullins. The UBX domain mediates interaction with VCP/p97. The UBA domain is required for binding ubiquitinated-protein substrates.

RefSeq proteins (1): NP_056377* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001012	UBX_dom	Domain
IPR006577	UAS	Domain
IPR009060	UBA-like_sf	Homologous_superfamily
IPR017346	UBX_7/2	Family
IPR029071	Ubiquitin-like_domsf	Homologous_superfamily
IPR036249	Thioredoxin-like_sf	Homologous_superfamily
IPR050730	UBX_domain-protein	Family
IPR054109	UBA_8	Domain

Pfam: PF00789, PF13899, PF22566

UniProt features (49 total): helix 11, strand 9, turn 7, modified residue 6, cross-link 3, mutagenesis site 3, domain 3, compositionally biased region 3, region of interest 2, initiator methionine 1, chain 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
5X3P	X-RAY DIFFRACTION	2
5X4L	X-RAY DIFFRACTION	2.4
1WJ4	SOLUTION NMR
2DAL	SOLUTION NMR
2DLX	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O94888-F1	73.78	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (9): 2, 278, 280, 285, 288, 306, 84, 99, 134

Mutagenesis-validated functional residues (3):

Position	Phenotype
288	no effect on interactions with cul2 and hif1a.
297	severely reduces interaction with neddylated cul2.
459	abolishes interaction with vcp/p97.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-8951664	Neddylation
R-HSA-9755511	KEAP1-NFE2L2 pathway

MSigDB gene sets: 119 (showing top): BORCZUK_MALIGNANT_MESOTHELIOMA_UP, DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, BACOLOD_RESISTANCE_TO_ALKYLATING_AGENTS_DN, DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_DN, PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP, BOYAULT_LIVER_CANCER_SUBCLASS_G1_UP, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS, GOBP_PROTEIN_CATABOLIC_PROCESS, NUYTTEN_EZH2_TARGETS_DN, MORF_RFC1, GOCC_ATPASE_COMPLEX, GOCC_MEMBRANE_PROTEIN_COMPLEX, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK, GOBP_PROTEOLYSIS

GO Biological Process (1): proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)

GO Molecular Function (4): ubiquitin protein ligase binding (GO:0031625), ubiquitin binding (GO:0043130), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), VCP-NPL4-UFD1 AAA ATPase complex (GO:0034098)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Post-translational protein modification	1
Cellular response to chemical stress	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
ubiquitin-like protein ligase binding	1
ubiquitin-like protein binding	1
DNA-binding transcription factor binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1
endoplasmic reticulum membrane	1
UFD1-NPL4 complex	1
membrane protein complex	1
endoplasmic reticulum protein-containing complex	1

Protein interactions and networks

STRING

3271 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
UBXN7	UFD1	Q92890	827
UBXN7	NPLOC4	Q8TAT6	812
UBXN7	FAF2	Q96CS3	801
UBXN7	UBXN1	Q04323	745
UBXN7	UBXN6	Q9BZV1	744
UBXN7	WDR53	Q7Z5U6	736
UBXN7	VCP	P55072	722
UBXN7	UBXN2A	P68543	710
UBXN7	CUL2	Q13617	690
UBXN7	SMCO1	Q147U7	690
UBXN7	UBXN10	Q96LJ8	648
UBXN7	UBXN8	O00124	646
UBXN7	ASPSCR1	Q9BZE9	624
UBXN7	UBXN4	Q92575	620
UBXN7	UBXN2B	Q14CS0	605

IntAct

130 interactions, top by confidence:

A	B	Type	Score
UBXN7	VCP	psi-mi:“MI:0915”(physical association)	0.820
UBXN7	VCP	psi-mi:“MI:0914”(association)	0.820
VCP	UBXN7	psi-mi:“MI:0914”(association)	0.820
UBXN7	CUL2	psi-mi:“MI:0914”(association)	0.710
UBXN7	CUL2	psi-mi:“MI:0915”(physical association)	0.710
CUL2	UBXN7	psi-mi:“MI:0914”(association)	0.710
TGIF2LY	PGP	psi-mi:“MI:0914”(association)	0.640
NUAK2	PPP1R12A	psi-mi:“MI:0914”(association)	0.640
UBXN7	CUL4A	psi-mi:“MI:0915”(physical association)	0.620
UBXN7	CUL3	psi-mi:“MI:0915”(physical association)	0.620
CUL4A	UBXN7	psi-mi:“MI:0914”(association)	0.620
UBXN7		psi-mi:“MI:0407”(direct interaction)	0.590
UBXN7		psi-mi:“MI:0914”(association)	0.590

BioGRID (371): UBC (Affinity Capture-Western), UBC (Reconstituted Complex), VCP (Affinity Capture-Western), UBC (Affinity Capture-Western), CUL2 (Reconstituted Complex), UBXN7 (Biochemical Activity), UBXN7 (Affinity Capture-MS), UBXN7 (Affinity Capture-MS), UBXN7 (Affinity Capture-Western), UBXN7 (Affinity Capture-Western), UBXN7 (Affinity Capture-Western), ACAD11 (Affinity Capture-Western), ERCC3 (Affinity Capture-Western), CSNK1G3 (Affinity Capture-Western), UBXN7 (Affinity Capture-Western)

ESM2 similar proteins: A4FUF0, A4Q9F4, D2XV59, E1C1R4, O94888, O95267, P42694, P54198, P79987, Q15139, Q49A26, Q4R8V9, Q4SS66, Q562D5, Q5R372, Q5R5M3, Q5R7T2, Q5RDU9, Q5REY7, Q5RKH0, Q5RKN4, Q5T6S3, Q5ZIA0, Q5ZJ17, Q5ZLS2, Q5ZLS7, Q61666, Q62101, Q6DC64, Q6DFV5, Q6P5G6, Q6ZPY2, Q6ZWH5, Q70Z35, Q75Q39, Q80VL1, Q86W50, Q8BY87, Q8BYN5, Q8CIW5

Diamond homologs: O14048, O94888, P0DKI5, Q06682, Q55BU7, Q5REY7, Q6P5G6, P0DKI4, P54731, Q924K2, Q94HV8, Q94JZ8, Q9M0N1, Q9UNN5, Q9LUG7, O00124, F4JPR7, O74498, Q3TDN2, Q5BK32, Q6AZH6, Q6GQ69, Q9C5G7, Q4V3D3

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 73 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha	5	24.0×	2e-04
KEAP1-NFE2L2 pathway	5	14.7×	1e-03
Neddylation	12	13.9×	9e-09
Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide	5	13.0×	2e-03
Cargo recognition for clathrin-mediated endocytosis	5	12.8×	2e-03
Antigen processing: Ubiquitination & Proteasome degradation	10	9.1×	2e-05
Ub-specific processing proteases	6	7.8×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of protein ubiquitination	5	18.4×	8e-04
G1/S transition of mitotic cell cycle	5	17.3×	9e-04
ubiquitin-dependent protein catabolic process	9	11.5×	2e-05
protein polyubiquitination	5	9.9×	5e-03
proteasome-mediated ubiquitin-dependent protein catabolic process	11	9.9×	6e-06
protein ubiquitination	11	7.8×	2e-05
positive regulation of canonical NF-kappaB signal transduction	6	7.5×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	34
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2298 predictions. Top by Δscore:

Variant	Effect	Δscore
3:196351410:T:A	donor_gain	1.0000
3:196356695:T:TA	donor_gain	1.0000
3:196356771:T:A	donor_gain	1.0000
3:196361836:GTACT:G	donor_loss	1.0000
3:196361837:TACTT:T	donor_loss	1.0000
3:196361838:ACT:A	donor_loss	1.0000
3:196361839:CTTAC:C	donor_loss	1.0000
3:196361840:TTAC:T	donor_loss	1.0000
3:196361842:A:AC	donor_gain	1.0000
3:196361842:ACTAG:A	donor_gain	1.0000
3:196361843:C:A	donor_loss	1.0000
3:196361843:C:CA	donor_gain	1.0000
3:196361843:CT:C	donor_gain	1.0000
3:196361843:CTA:C	donor_gain	1.0000
3:196361843:CTAG:C	donor_gain	1.0000
3:196361843:CTAGC:C	donor_gain	1.0000
3:196361922:TC:T	acceptor_gain	1.0000
3:196361923:CC:C	acceptor_gain	1.0000
3:196361924:C:A	acceptor_loss	1.0000
3:196361924:C:CC	acceptor_gain	1.0000
3:196361937:T:C	acceptor_gain	1.0000
3:196361937:T:TC	acceptor_gain	1.0000
3:196362289:CTTA:C	donor_loss	1.0000
3:196362290:TTA:T	donor_loss	1.0000
3:196362291:TAC:T	donor_loss	1.0000
3:196362292:AC:A	donor_gain	1.0000
3:196362293:CC:C	donor_gain	1.0000
3:196362683:CTCTC:C	acceptor_gain	1.0000
3:196362685:CTC:C	acceptor_gain	1.0000
3:196362695:A:AC	acceptor_gain	1.0000

AlphaMissense

3226 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:196356701:A:T	V485E	1.000
3:196356703:A:C	F484L	1.000
3:196356703:A:T	F484L	1.000
3:196356705:A:G	F484L	1.000
3:196356707:A:T	V483D	1.000
3:196356725:A:G	L477P	1.000
3:196356725:A:T	L477H	1.000
3:196356767:A:G	L463S	1.000
3:196356779:G:T	P459H	1.000
3:196356780:G:A	P459S	1.000
3:196356781:A:C	F458L	1.000
3:196356781:A:T	F458L	1.000
3:196356782:A:C	F458C	1.000
3:196356782:A:G	F458S	1.000
3:196356783:A:G	F458L	1.000
3:196361899:C:G	R418P	1.000
3:196362629:A:G	L298S	1.000
3:196362632:G:A	S297F	1.000
3:196362633:A:G	S297P	1.000
3:196362636:C:G	A296P	1.000
3:196362641:A:C	I294S	1.000
3:196362641:A:G	I294T	1.000
3:196362641:A:T	I294N	1.000
3:196362644:G:T	A293D	1.000
3:196362645:C:G	A293P	1.000
3:196362648:C:G	A292P	1.000
3:196362653:A:G	L290P	1.000
3:196362655:C:A	Q289H	1.000
3:196362655:C:G	Q289H	1.000
3:196362672:C:G	A284P	1.000

dbSNP variants (sampled 300 via entrez): RS1000057824 (3:196381977 A>G), RS1000087217 (3:196394631 A>C), RS1000118607 (3:196421942 T>C), RS1000146078 (3:196349055 G>A), RS1000169263 (3:196412790 C>T), RS1000184046 (3:196369075 C>T), RS1000187431 (3:196398279 T>C), RS1000195240 (3:196412440 G>C), RS1000204283 (3:196410099 C>A,T), RS1000214077 (3:196408017 G>A), RS1000255057 (3:196400095 A>G,T), RS1000268423 (3:196418242 A>G), RS1000299764 (3:196404001 T>C), RS1000317426 (3:196405941 T>A,C), RS1000328789 (3:196404338 C>T)

Disease associations

OMIM: gene MIM:616379 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST001762_159	Obesity-related traits	7.000000e-06
GCST008575_9	IgM levels	2.000000e-12
GCST010241_246	Apolipoprotein A1 levels	4.000000e-09
GCST010242_385	HDL cholesterol levels	4.000000e-10
GCST010988_223	Adult body size	2.000000e-10

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004338	body weight
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004612	high density lipoprotein cholesterol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression	2
GSK-J4	increases expression	1
FR900359	increases phosphorylation	1
bisphenol F	affects cotreatment, decreases expression	1
bisphenol A	increases methylation	1
sodium arsenate	decreases expression	1
butyraldehyde	decreases expression	1
coumarin	decreases phosphorylation	1
pentanal	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
jinfukang	decreases expression	1
LDN 193189	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Arsenic	increases abundance, increases expression	1
Cadmium	increases abundance, increases expression	1
Caffeine	affects phosphorylation	1
Dexamethasone	affects cotreatment, decreases expression	1
Doxorubicin	increases expression	1
Drugs, Chinese Herbal	increases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Indomethacin	affects cotreatment, decreases expression	1
Ivermectin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Naphthoquinones	increases expression	1
Quercetin	increases phosphorylation	1
Urethane	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.